Neuropace share price today

(NPCE)

Neuropace share price is $11.93 & ₹1,023.71 as on 7 Jan 2025, 2.30 'hrs' IST

$11.93

▲

0.36

(3.11%)

Market is closed - opens 8 PM, 07 Jan 2025

View live Neuropace share price in Dollar and Rupees. Guide to invest in Neuropace stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Neuropace, along with analyst recommendations, forecasts, and comprehensive financials.

Neuropace share price movements

Today's Low: $11.52
Today's High: $12.53
$11.93
3.44%
Downside
Day's Volatility :8.02%
Upside
4.75%
52 Weeks Low: $5.45
52 Weeks High: $18.15
$11.93
54.32%
Downside
52 Weeks Volatility :69.97%
Upside
34.27%

Neuropace Returns

Period	Neuropace Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	80.22%	-8.4%	0.0%
6 Months	73.98%	-3.8%	0.0%
1 Year	-6.32%	-0.1%	0.0%
3 Years	15.24%	2.9%	-19.8%

Neuropace Key Statistics

in dollars & INR

Previous Close	$11.57
Open	$11.65
Today's High	$12.525
Today's Low	$11.52
Market Capitalization	$334.0M
Today's Volume	$41.7K
52 Week High	$18.15
52 Week Low	$5.45
Revenue TTM	$76.5M
EBITDA	$-22.9M
Earnings Per Share (EPS)	$-0.98
Profit Margin	-36.74%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-214.55%

How to invest in Neuropace from India?

It is very easy for Indian residents to invest directly in Neuropace from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Neuropace stock in both Indian Rupees (INR) and US Dollars (USD). Search for Neuropace or NPCE on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Neuropace or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Neuropace shares which would translate to 0.072 fractional shares of Neuropace as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Neuropace, in just a few clicks!

Returns in Neuropace for Indian investors in Rupees

Investment Value

₹1,00,000

Neuropace investment value today

Current value as on today

₹99,822

Returns

₹178

(-0.18%)

Returns from Neuropace Stock

₹3,401 (-3.4%)

Dollar Returns

₹3,223 (+3.22%)

Indian investors sentiment towards Neuropace

-10%

Period: Oct 8, 2024 to Jan 6, 2025. Change in 30 Days versus previous period

Search volume for Neuropace on INDmoney from India has reduced in the last 30 days as on Jan 7, 2025. -10% less investors are searching Neuropace in the last 30 days versus the previous period.

Global Institutional Holdings in Neuropace

Orbimed Advisors, LLC
11.41%
Morgan Stanley - Brokerage Accounts
8.36%
Soleus Capital Management, L.P.
8.15%
Kent Lake Capital LLC
3.83%
Vanguard Group Inc
3.33%
Millennium Management LLC
2.48%

Analyst Recommendation on Neuropace

Buy

84%Buy

15%Hold

0%Sell

Based on 13 Wall street analysts offering stock ratings for Neuropace(by analysts ranked 0 to 5 stars)

Based on 13 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Neuropace

What analysts predicted

Upside of 35.51%

Current:

$11.93

Target:

$16.17

Insights on Neuropace

Price Movement
In the last 3 months, NPCE stock has moved up by 69.4%
Increasing Revenue
Revenue is up for the last 5 quarters, 16.42M → 21.06M (in $), with an average increase of 6.0% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -8.92M → -5.45M (in $), with an average increase of 28.3% per quarter
NPCE vs BSX (1 yr)
In the last 1 year, Boston Scientific Corp. has given 55.9% return, outperforming this stock by 50.1%
NPCE vs BSX (3 yr)
In the last 3 years, Boston Scientific Corp. has given 112.9% return, outperforming this stock by 112.9%
Price to Sales
ForNPCE every $1 of sales, investors are willing to pay $4.3, whereas for Boston Scientific Corp., the investors are paying $8.4 for every $1 of sales.

Neuropace Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$37.0M	-
Net Income	$-40.7M	-
Net Profit Margin	-110.19%	-

	FY20	Y/Y Change
Revenue	$41.1M	↑ 11.27%
Net Income	$-36.0M	↓ 11.68%
Net Profit Margin	-87.47%	↑ 22.72%

	FY21	Y/Y Change
Revenue	$45.2M	↑ 9.83%
Net Income	$-38.1M	↑ 5.91%
Net Profit Margin	-84.34%	↑ 3.13%

	FY22	Y/Y Change
Revenue	$45.5M	↑ 0.75%
Net Income	$-53.4M	↑ 40.05%
Net Profit Margin	-117.25%	↓ 32.91%

	FY23	Y/Y Change
Revenue	$65.4M	↑ 43.72%
Net Income	$-33.0M	↓ 38.25%
Net Profit Margin	-50.38%	↑ 66.87%

	Q2 FY23	Q/Q Change
Revenue	$16.5M	↑ 14.08%
Net Income	$-9.1M	↓ 36.62%
Net Profit Margin	-55.26%	↑ 44.21%

	Q3 FY23	Q/Q Change
Revenue	$16.4M	↓ 0.5%
Net Income	$-7.3M	↓ 20.46%
Net Profit Margin	-44.18%	↑ 11.08%

	Q4 FY23	Q/Q Change
Revenue	$18.0M	↑ 9.65%
Net Income	$-6.2M	↓ 14.57%
Net Profit Margin	-34.42%	↑ 9.76%

	Q1 FY24	Q/Q Change
Revenue	$18.1M	↑ 0.62%
Net Income	$-8.9M	↑ 43.95%
Net Profit Margin	-49.24%	↓ 14.82%

	Q2 FY24	Q/Q Change
Revenue	$19.3M	↑ 6.25%
Net Income	$-7.5M	↓ 15.81%
Net Profit Margin	-39.02%	↑ 10.22%

	Q3 FY24	Q/Q Change
Revenue	$21.1M	↑ 9.37%
Net Income	$-5.5M	↓ 27.44%
Net Profit Margin	-25.89%	↑ 13.13%

	FY19	Y/Y Change
Profit	$26.5M	-

	FY20	Y/Y Change
Profit	$30.3M	↑ 14.39%

	FY21	Y/Y Change
Profit	$33.4M	↑ 10.45%

	FY22	Y/Y Change
Profit	$32.5M	↓ 2.82%

	FY23	Y/Y Change
Profit	$48.1M	↑ 48.1%

	Q2 FY23	Q/Q Change
Profit	$12.0M	↑ 15.43%

	Q3 FY23	Q/Q Change
Profit	$12.2M	↑ 2.18%

	Q4 FY23	Q/Q Change
Profit	$13.5M	↑ 10.73%

	Q1 FY24	Q/Q Change
Profit	$13.3M	↓ 1.49%

	Q2 FY24	Q/Q Change
Profit	$14.1M	↑ 5.93%

	Q3 FY24	Q/Q Change
Profit	$15.4M	↑ 9.1%

	FY19	Y/Y Change
Operating Cash Flow	$-25.0M	-
Investing Cash Flow	$3.6M	-
Financing Cash Flow	$21.4M	-

	FY20	Y/Y Change
Operating Cash Flow	$-21.6M	↓ 13.65%
Investing Cash Flow	$-10.8M	↓ 397.6%
Financing Cash Flow	$55.0M	↑ 157.41%

	FY21	Y/Y Change
Operating Cash Flow	$-24.6M	↑ 13.74%
Investing Cash Flow	$-85.4M	↑ 693.13%
Financing Cash Flow	$102.5M	↑ 86.38%

	FY22	Y/Y Change
Operating Cash Flow	$-36.9M	↑ 50.01%
Investing Cash Flow	$23.8M	↓ 127.87%
Financing Cash Flow	$490.0K	↓ 99.52%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-4.4M	↓ 55.04%
Investing Cash Flow	$5.3M	↓ 47.36%
Financing Cash Flow	$195.0K	↓ 176.47%

Neuropace Technicals Summary

Sell

Neutral

Buy

Neuropace is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Neuropace Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Neuropace Inc	5.66%	73.98%	-6.32%	15.24%	-53.65%
Stryker Corporation	-5.14%	7.73%	20.51%	37.02%	70.83%
Boston Scientific Corp.	2.22%	18.53%	55.24%	113.84%	98.4%
Edwards Lifesciences Corp.	4.25%	-20.93%	-2.33%	-38.47%	-5.21%
Abbott Laboratories	-0.93%	11.99%	1.27%	-15.84%	31.69%
Medtronic Plc	-3.59%	5.29%	-6.49%	-23.36%	-31.62%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Neuropace Inc	NA	NA	NA	-1.01	-2.15	-0.15	NA	0.33
Stryker Corporation	38.59	38.59	2.51	12.06	0.19	0.07	0.01	52.86
Boston Scientific Corp.	73.82	73.82	1.62	2.46	0.09	0.05	NA	14.05
Edwards Lifesciences Corp.	28.0	28.0	6.67	2.54	0.19	0.11	NA	16.18
Abbott Laboratories	34.38	34.38	2.19	4.68	0.15	0.06	0.02	22.94
Medtronic Plc	24.43	24.43	1.46	5.45	0.08	0.04	0.03	38.29

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Neuropace Inc	Buy	$334.0M	-53.65%	NA	-36.74%
Stryker Corporation	Buy	$137.3B	70.83%	38.59	16.34%
Boston Scientific Corp.	Buy	$131.6B	98.4%	73.82	11.26%
Edwards Lifesciences Corp.	Buy	$43.6B	-5.21%	28.0	65.86%
Abbott Laboratories	Buy	$196.2B	31.69%	34.38	13.99%
Medtronic Plc	Buy	$102.4B	-31.62%	24.43	12.06%

About Neuropace

the rns® system is an award-winning technology developed and manufactured in silicon valley that has been recognized for its innovation. similar to a pacemaker that monitors and responds to heart rhythms, the rns system is the world's first and only medical device that can monitor and respond to brain activity. neuropace was founded to design, develop, manufacture and market implantable devices for the treatment of neurological disorders with responsive stimulation. the company's initial focus is the treatment of epilepsy, a debilitating neurological disorder affecting approximately 1% of the population worldwide.in addition to treating epilepsy, responsive neurostimulation holds the promise of treating several other disabling medical disorders that impact the quality of life for millions of patients around the world.

Organization	Neuropace
Employees	184
CEO	Mr. Joel D. Becker
Industry	Healthcare

Management People of Neuropace

Name	Title
Mr. Joel D. Becker	CEO, President & Director
Ms. Rebecca L. Kuhn	CFO, VP of Finance & Administration
Dr. Martha J. Morrell M.D.	Chief Medical Officer
Mr. Dylan St. John	Chief of Operations & Development
Ms. Leah Akin	General Counsel & Corporate Secretary
Ms. Kelley Nicholas	Vice President of Sales
Ms. Amy Treadwell	Vice President of Human Resources

Important FAQs about investing in Neuropace from India :

What is Neuropace share price today?

Neuropace share price today stands at $11.93, Open: $11.65 ; Previous Close: $11.57 ; High: $12.53 ; Low: $11.52 ; 52 Week High: $18.15 ; 52 Week Low: $5.45. The stock opens at $11.65, after a previous close of $11.57. The stock reached a daily high of $12.53 and a low of $11.52, with a 52-week high of $18.15 and a 52-week low of $5.45.

Can Indians buy Neuropace shares?

Yes, Indians can invest in the Neuropace (NPCE) from India.

With INDmoney, you can buy Neuropace at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Neuropace at zero transaction cost.

How can I buy Neuropace shares from India?

It is very easy to buy Neuropace from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Neuropace be purchased?

Yes, you can buy fractional shares of Neuropace with INDmoney app.

What are the documents required to start investing in Neuropace stocks?

To start investing in Neuropace, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.